Eli Lilly & Co.’s antibody therapy reduced nursing home residents’ risk of symptomatic Covid-19 by as much as 80% when used preventively in a study.
The infused treatment, cleared for use in high-risk Covid patients with mild-to-moderate disease who haven’t been hospitalized, also significantly reduced the risk of symptomatic disease in nursing home workers, according to a statement from Lilly on Thursday.
The U.S. is prioritizing Covid-19 vaccines from Moderna Inc., Pfizer Inc. and other manufacturers for elderly people and health-care workers. The results suggest that Lilly’s treatment, called bamlanivimab, may also play a role in the effort to keep nursing home patients and staff from developing severe, potentially lethal illness.
With more than 400,000 deaths since the outset of the pandemic, the U.S. is the world leader in Covid mortality. Nursing home residents represent about a quarter of those fatalities, according to data from the Centers for Medicare & Medicaid Services.